Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 01 04:00PM ET
7.28
Dollar change
-0.04
Percentage change
-0.55
%
IndexRUT P/E- EPS (ttm)-1.22 Insider Own20.51% Shs Outstand105.65M Perf Week-1.62%
Market Cap764.96M Forward P/E- EPS next Y-1.14 Insider Trans-0.05% Shs Float83.99M Perf Month17.23%
Income-115.16M PEG- EPS next Q-0.26 Inst Own86.36% Short Float10.62% Perf Quarter34.57%
Sales0.00M P/S- EPS this Y44.76% Inst Trans20.75% Short Ratio7.48 Perf Half Y49.18%
Book/sh3.42 P/B2.13 EPS next Y-16.54% ROA-36.04% Short Interest8.92M Perf Year203.33%
Cash/sh3.51 P/C2.07 EPS next 5Y38.60% ROE-42.20% 52W Range2.05 - 8.40 Perf YTD60.35%
Dividend Est.- P/FCF- EPS past 5Y-29.69% ROI-29.61% 52W High-13.33% Beta1.23
Dividend TTM- Quick Ratio21.81 Sales past 5Y0.00% Gross Margin- 52W Low255.99% ATR (14)0.33
Dividend Ex-Date- Current Ratio21.81 EPS Y/Y TTM38.27% Oper. Margin0.00% RSI (14)54.32 Volatility3.13% 4.87%
Employees71 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price15.50
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q51.36% Payout- Rel Volume0.58 Prev Close7.32
Sales Surprise- EPS Surprise-0.22% Sales Q/Q- EarningsAug 12 BMO Avg Volume1.19M Price7.28
SMA20-0.60% SMA508.76% SMA20027.83% Trades Volume686,141 Change-0.55%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Upgrade JP Morgan Neutral → Overweight $11
Dec-21-23Upgrade BofA Securities Neutral → Buy $4 → $6
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Oct-21-24 08:00PM
Oct-16-24 08:00AM
Oct-15-24 08:00AM
Sep-16-24 08:00AM
Sep-09-24 08:00AM
08:00AM Loading…
Sep-03-24 08:00AM
Aug-29-24 08:00AM
Aug-16-24 04:05PM
Aug-12-24 08:00AM
Aug-05-24 08:00AM
Jul-16-24 04:05PM
Jul-11-24 06:09PM
Jun-29-24 08:48PM
Jun-28-24 09:40AM
Jun-27-24 09:55AM
05:00PM Loading…
Jun-25-24 05:00PM
05:00PM
Jun-24-24 06:35AM
Jun-18-24 08:00AM
Jun-17-24 04:05PM
Jun-07-24 09:40AM
Jun-05-24 11:04PM
10:57AM
09:55AM
04:45AM
Jun-04-24 05:06PM
12:06PM
08:46AM
07:28AM
07:00AM
07:00AM Loading…
07:00AM
Jun-03-24 04:30PM
May-20-24 09:35AM
May-16-24 04:05PM
May-13-24 02:53PM
08:00AM
May-09-24 08:00AM
May-07-24 12:30PM
May-01-24 10:15AM
08:00AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Love DouglasPRESIDENT AND CEOOct 30 '24Option Exercise1.85114,449211,742310,570Nov 01 04:15 PM
Yednock TedEVP & CHIEF INNOVATION OFFICEROct 15 '24Option Exercise1.855,40810,00576,773Oct 17 05:09 PM
Yednock TedEVP & CHIEF INNOVATION OFFICEROct 15 '24Sale7.415,40840,07371,365Oct 17 05:09 PM
Yednock TedOfficerOct 15 '24Proposed Sale7.415,40840,073Oct 15 02:03 PM
Carson William H.DirectorOct 01 '24Buy5.973,20019,10422,400Oct 02 04:15 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERSep 19 '24Sale7.104,50031,9500Sep 20 04:30 PM
Yednock TedOfficerSep 19 '24Proposed Sale7.104,50031,950Sep 19 12:32 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERSep 12 '24Sale6.165,50033,8804,500Sep 16 04:30 PM
Yednock TedOfficerSep 12 '24Proposed Sale6.165,50033,880Sep 12 10:24 AM
Yednock TedEVP & CHIEF INNOVATION OFFICERSep 05 '24Sale5.645,50031,02010,000Sep 06 04:30 PM
Yednock TedOfficerSep 05 '24Proposed Sale5.645,50031,020Sep 05 10:15 AM
Carson William H.DirectorSep 03 '24Buy5.483,20017,53619,200Sep 04 04:34 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERAug 29 '24Sale5.955,50032,72515,500Aug 30 06:00 PM
Yednock TedOfficerAug 29 '24Proposed Sale5.955,50032,725Aug 29 02:08 PM
Carson William H.DirectorAug 01 '24Buy6.243,20019,96816,000Aug 05 07:53 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERJul 15 '24Sale6.027844,72094,622Jul 17 04:49 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERJul 15 '24Sale6.031,1046,65786,468Jul 17 04:48 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERJul 15 '24Sale6.021,1066,65871,365Jul 17 04:46 PM
Carson William H.DirectorJul 01 '24Buy5.003,20016,00012,800Jul 02 05:43 PM
Carson William H.DirectorJun 03 '24Buy4.833,20015,4599,600Jun 05 04:23 PM
Carson William H.DirectorMay 01 '24Buy4.683,20014,9826,400May 03 04:15 PM
Carson William H.DirectorApr 08 '24Buy6.073,20019,4113,200Apr 10 07:17 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 20 '24Sale5.532,59314,33982,058Feb 21 04:31 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 20 '24Sale5.512,60414,34872,471Feb 21 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 20 '24Sale5.481,95110,69185,641Feb 21 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 12 '24Sale5.531,3497,46048,592Feb 14 07:59 PM
Love DouglasPRESIDENT AND CEOFeb 12 '24Sale5.545,78232,032196,121Feb 14 07:56 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 12 '24Sale5.541,80910,02245,651Feb 14 07:54 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 12 '24Sale5.541,81010,02736,075Feb 14 07:52 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Option Exercise1.6321,00034,17621,000Dec 29 04:12 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Sale4.5221,00094,9660Dec 29 04:12 PM
Satter Muneer ADirectorDec 26 '23Buy2.88350,0001,008,0007,406,024Dec 28 04:30 PM
Last Close
Nov 01 04:00PM ET
1.32
Dollar change
+0.05
Percentage change
3.94
%
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-2.11 Insider Own51.52% Shs Outstand27.61M Perf Week38.95%
Market Cap60.30M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float21.31M Perf Month81.94%
Income-65.53M PEG- EPS next Q-0.25 Inst Own14.59% Short Float0.49% Perf Quarter43.99%
Sales2.36M P/S25.55 EPS this Y54.80% Inst Trans4.21% Short Ratio0.50 Perf Half Y11.86%
Book/sh0.76 P/B1.74 EPS next Y54.11% ROA-71.92% Short Interest0.10M Perf Year-42.75%
Cash/sh1.64 P/C0.80 EPS next 5Y- ROE-130.03% 52W Range0.49 - 2.89 Perf YTD140.00%
Dividend Est.- P/FCF- EPS past 5Y-44.91% ROI-159.90% 52W High-54.39% Beta-0.20
Dividend TTM- Quick Ratio2.02 Sales past 5Y0.00% Gross Margin23.76% 52W Low169.39% ATR (14)0.12
Dividend Ex-Date- Current Ratio2.02 EPS Y/Y TTM31.42% Oper. Margin-2830.04% RSI (14)71.68 Volatility16.24% 12.11%
Employees73 Debt/Eq0.26 Sales Y/Y TTM- Profit Margin-2780.27% Recom1.33 Target Price5.50
Option/ShortNo / Yes LT Debt/Eq0.23 EPS Q/Q65.78% Payout- Rel Volume1.43 Prev Close1.27
Sales Surprise-92.14% EPS Surprise-4.35% Sales Q/Q- EarningsAug 08 BMO Avg Volume209.40K Price1.32
SMA2043.73% SMA5055.91% SMA20045.92% Trades Volume299,798 Change3.94%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Oct-30-24 09:01AM
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
04:05PM Loading…
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM Loading…
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
07:30AM Loading…
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.647334692,019,563Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.64267171734,546Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.871,5661,3622,021,836Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.831,5401,2782,020,296Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.87569495735,373Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.83560465734,813Jan 16 06:16 PM